Results 131 to 140 of about 1,353,967 (265)
A Bayesian Two-Step Multiple Imputation Approach Based on Mixed Models for Missing EMA Data. [PDF]
Wei Y, Siddique J, Spring B, Hedeker D.
europepmc +1 more source
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner +14 more
wiley +1 more source
Multi-response phylogenetic mixed models: concepts and application. [PDF]
Halliwell B, Holland BR, Yates LA.
europepmc +1 more source
glmmPen: High Dimensional Penalized Generalized Linear Mixed Models. [PDF]
Heiling HM, Rashid NU, Li Q, Ibrahim JG.
europepmc +1 more source
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel +12 more
wiley +1 more source
Bayesian Mixed Models Approach to Exploring Resilience: Impact of Stress on Subjective Health and Affects Over Time During the COVID-19 Pandemic. [PDF]
Schepers M +10 more
europepmc +1 more source
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Selecting stable rice mutants with linear mixed models (LMM) and stability indexes. [PDF]
Sharifi P +3 more
europepmc +1 more source
Incorporating Linear Mixed Models into GWAS of Kidney Function Decline. [PDF]
Lanktree MB.
europepmc +1 more source
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source

